AC8 has all the necessary licenses to grow and manufacture cannabinoid medicines in Australia.
() has entered into a supply agreement to purchase cannabis resin from Corporation (TSXV:LABS) (OTCQB:MLCPF).
The high-grade cannabis resin will primarily be used in the manufacture of AusCann’s first product line of hard-shell cannabinoid capsules.
MediPharm is Canada’s largest and most experienced supplier of purified, pharmaceutical grade cannabis extracts.
Its state-of-the-art facility is one of the most innovative and technically advanced in the cannabis industry.
First supply under the deal is set to commence in the coming months.
READ: AusCann Group on track to produce cannabinoid medicines this year
AusCann’s interim CEO Dr Paul MacLeman said: “Reliable supply of pharma-grade cannabinoid extracts through MediPharm’s proprietary methodologies will support AusCann’s ability to develop and deliver quality cannabinoid medicines.
"Critical for the company are repeatability in manufacturing, reliable dosing, and purity assurance.
“These product foundations will allow delivery of effective, trusted and safe medicines for the treatment of chronic pain.”
Plans for multiple suppliers to lower risk
AusCann is working towards securing a small number of validated, safe and reliable sources of cannabis resins as ongoing inputs into its pharmaceutical product development, clinical trials and product sales activities.
This multi-supplier strategy mitigates and reduces supply risks and enables AusCann to work efficiently with specialists in different types of extracts across a number of jurisdictions.
It also supports AusCann’s focus upon novel dose form development to optimise patient outcomes and create valuable pharmaceutical products for the Australian and export markets.
